Table 2 Weekly overall growth rates of AZD4625 versus vehicle (>1: growing; <1: shrinking) based on loglinear mixed effect models

From: Modeling response to the KRAS-G12C inhibitor AZD4625 in KRASG12C NSCLC patient-derived xenografts reveals insights into primary resistance mechanisms

Model (PHLC ID)

Vehicle,

Rate of change in volume per week

AZD4625,

Rate of change in volume per week

AZD4625 in vivo Sensitivity

82

1.13

0.90

Sensitive

151

1.43

0.80

Sensitive

194

1.33

0.90

Sensitive

207

1.58

0.87

Sensitive

239

1.48

1.21

Resistant

277

1.72

1.32

Resistant

191

2.91

1.83

Resistant

256

1.44

1.18

Resistant

334

1.48

1.18

Resistant

362

1.32

1.10

Resistant

237

1.41

1.34

Resistant

344

1.38

1.29

Resistant